Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma
Abstract Predictive factors for response to regorafenib in recurrent glioblastoma, IDH-wildtype, are scarcely recognized.The objective of this study was to identify molecular predictive factors for response to regorafenib using a clinically available platform.We analyzed a TAPIOCA FLOUR prospective cohort of 30 patients harboring recurrent glioblas